Hizentra Is a Subcutaneous Ig Therapy You Infuse Yourself

It's called a subcutaneous immunoglobulin, or SCIg, infusion, in which you infuse Ig treatment into the fatty tissue just below your skin's first layer. Do not infuse Hizentra into your vein.

  • A dose of Hizentra may be infused into multiple injection sites. Use up to 4 sites simultaneously or up to 12 sites consecutively per infusion. Injection sites should be at least 2 inches apart. Change the actual site of injection with each administration.
  • Recommended infusion sites include the stomach, thighs, upper arms, or hips. Your healthcare professional will teach you how to properly administer Hizentra
  • Sub-Q needles are smaller than IV needles. Depending on your size and weight, your doctor will recommend a needle as short as 4 mm or as long as 14 mm
Subcutaneous Infusion Sites

Self-Infusing at Home

Your healthcare provider will teach you how to infuse Hizentra over the course of several weeks. Make sure you're comfortable with the process before doing your own infusions.

Equipment You'll Need to Self-Administer Hizentra

Your nurse or specialty pharmacy will provide the necessary equipment to infuse Hizentra. Supplies include, but are not limited to: an infusion pump, syringe and needle, plastic tubing, container for syringe disposal, sterile gauze pad, and alcohol pads.

Hear Carla Duff, ARNP Discuss Self-Administration With Her Patients

“When [patients] leave... they are confident in their ability that the next week when they do their infusion, they can do it themselves”

- Carla Duff, ARNP

Hear Prescribers Discuss Topics Surrounding SCIg Therapy

Hizentra Patient Welcome Kit

Order the Complete Hizentra Welcome Kit

This kit provides important resources to help you start and stay on Hizentra. Your welcome kit includes:

  1. Voice2Voice Brochure
  2. Hizentra Patient Brochure
  3. Hizentra Step-by-Step Infusion Guide
  4. Hizentra Therapy Journal
  5. CSL Behring Assurance Brochure
  6. MyHizentra Infusion Manager App Brochure
  7. Prescribing Information, including Patient Product Information
  8. Additional Information

Keep track of your therapy with this convenient app

The MyHizentra® Infusion Manager app will alert you when it's time to infuse. The app can even send you reminders on all cloud-synced devices (desktop, laptop, mobile phone) as part of your regular calendar.

Like Hizentra itself, the Infusion Manager app is flexible and designed to fit your lifestyle. You can use the app to manage your own infusions, and/or those of someone for whom you are a caregiver. You can also customize how you enter your infusion schedule and the time at which you would like to be reminded.

The app makes it easy for you to record your infusions, including scanning the QR code of each vial and giving you a place to write notes on each infusion. You’ll be able to review the digital record of your past infusions at any time.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Patient/Caregiver Using Hizentra
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ-0221-SEP17